KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations: 2011-2024

Historic Income from Continuing Operations for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$4.8 million.

  • Esperion Therapeutics' Income from Continuing Operations fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Esperion Therapeutics' Income from Continuing Operations amounted to -$4.8 million in FY2024, which was up 97.74% from -$214.5 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Income from Continuing Operations high stood at -$4.8 million for FY2024, and its period low was -$273.1 million during FY2021.
  • Over the past 3 years, Esperion Therapeutics' median Income from Continuing Operations value was -$214.5 million (recorded in 2023), while the average stood at -$151.9 million.
  • In the last 5 years, Esperion Therapeutics' Income from Continuing Operations slumped by 89.55% in 2021 and then skyrocketed by 97.74% in 2024.
  • Esperion Therapeutics' Income from Continuing Operations (Yearly) stood at -$144.1 million in 2020, then slumped by 89.55% to -$273.1 million in 2021, then climbed by 13.47% to -$236.3 million in 2022, then climbed by 9.21% to -$214.5 million in 2023, then spiked by 97.74% to -$4.8 million in 2024.